Alkermes Investigational Site
Orlando, Florida, 32809, United States
NCT Number: NCT02452801
This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Orlando, Florida, 32809, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For all subjects:
For subjects with hepatic impairment:
Exclusion criteria
For all subjects:
For subjects with hepatic impairment:
Single dose, given orally
Time frame: Up to 168 hours postdose
Time frame: Up to 168 hours postdose
Time frame: Up to 168 hours postdose
Time frame: Up to 168 hours postdose
Time frame: Up to 168 hours postdose
Time frame: Up to 168 hours postdose
Time frame: Up to 168 hours postdose
Time frame: Up to 14 weeks
Alkermes, Inc.
Industry
A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03289234
Healthy, Hepatic Impairment
Fukuoka, Japan
View Trial DetailsNCT04332432
Hepatic Impairment
Rialto, California, United States
View Trial DetailsNCT06736223
Hepatic Impairment
Sofia, Bulgaria
View Trial DetailsNCT06575959
Digestive System Diseases, Hepatic Impairment
Orlando, Florida, United States
View Trial Details